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Neurological diseases are due to the loss of structure or function of neu-
rons that eventually leads to cognitive deficit, neuropsychiatric symptoms,
and impaired activities of daily living. Identifying sensitive and specific bi-
ological and clinical markers for early diagnosis allows recruiting patients
into a clinical trial to test therapeutic intervention. However, many biomarker
studies considered a single biomarker at one time that fails to provide pre-
cise prediction for disease age at onset. In this paper, we use longitudinally
collected measurements from multiple biomarkers and measurement error-
corrected clinical diagnosis ages to identify which biomarkers and what fea-
tures of biomarker trajectories are useful for early diagnosis. Specifically,
we assume that the subject-specific biomarker trajectories depend on unob-
served states of underlying latent variables with the conditional mean fol-
lows a nonlinear sigmoid shape. We show that peak degeneration age of the
biomarker trajectory is useful for early diagnosis. We propose an Expectation-
Maximization (EM) algorithm to obtain the maximum likelihood estimates of
all parameters and conduct extensive simulation studies to examine the per-
formance of the proposed methods. Finally, we apply our methods to studies
of Alzheimer’s disease and Huntington’s disease and identify a few important
biomarkers that can be used for early diagnosis.
1. Introduction. Neurological diseases, such as Huntington’s disease (HD),
Alzheimer’s disease (AD), and Parkinson’s disease, involve the loss of structure or
function of neurons that eventually leads to cognitive deficit, motor impairment,
neuropsychiatric symptoms, and impaired activities of daily living. There are cur-
rently no disease-modifying treatments for these disorders since damaged neurons
cannot be replaced or reproduced. The pathophysiological process of the diseases
is thought to begin years before irremediable neuronal loss and cognitive deficits
manifest (Sperling et al. (2011)). Therefore, early diagnosis offers an opportunity
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for effective therapeutic intervention because the cognitive function might be pre-
served at the highest level possible before irreversible damage has occurred.
To develop effective therapeutics, it is important to identify biomarkers with the
most rapid change at the earliest age and also associated with clinical diagnosis.
Many subtle clinical features and biomarkers of preclinical pathological change
can potentially serve as early diagnostic or prognostic indicators. For example,
prognostic biomarkers in the motor, imaging, and cognitive domains are suggested
to be useful for predicting early motor or cognitive abnormalities in HD (Paulsen
et al. (2014a)). For AD, various neurobiological measures, such as cerebrospinal
fluid levels of Aβ42 and total tau protein, show preclinical alterations that predict
development of early AD symptoms (Hampel et al. (2008)). However, all these
findings are based on isolated analysis and it remains largely unknown which
biomarkers manifest significant changes prior to disease onset and for how long
before the onset.
To evaluate the relationship of changes in biomarkers and clinical diagnosis of
AD, Hall et al. (2000, 2001, 2003) modeled longitudinal measurements of one or
two biomarkers by change point polynomial mixed models, where the change point
is associated with the age of clinical diagnosis that is assumed to be observed for all
subjects. Later, Jacqmin-Gadda, Commenges and Dartigues (2006) extended the
methods to jointly model measurements of a biomarker and right-censored age of
clinical diagnosis. However, the change point only indicates the change of pattern
of the biomarker over time and may not necessarily be the acceleration time of the
biomarker change. Recently, an imputation-based analysis was used in Bateman
et al. (2012). In this method, the biomarker measurements were first aligned by
the age from the expected AD clinical diagnosis, and a cubic polynomial mixed
effects model was used to model the biomarker trajectory retrospectively. The ear-
liest time prior to the AD onset where a difference can be detected between mu-
tation carriers and noncarriers and when the maximal difference is detected were
considered as critical time points. There are several limitations with this analysis.
First, participants (children of parents who had AD and carried mutations associ-
ated with AD) were recruited before being diagnosed with AD, thus their onset
ages were censored. Bateman et al. (2012) imputed participant’s AD age at onset
using their parents’ age at onset since their approach does not handle censoring.
This imputation may introduce inaccuracy into the analysis. Second, the analysis
in Bateman et al. (2012) did not model multiple biomarkers simultaneously.
To model both longitudinal measurements and disease onset, joint modeling
approaches, including selection models and pattern mixture models (Little (1995),
Hogan and Laird (1997), Tsiatis and Davidian (2004)), have been extensively used.
However, since these joint modeling approaches rely on some shared random ef-
fects to link longitudinal biomarkers with disease age at onset, they are not useful
to identify any subject-specific biomarker features that are present prior to the
disease onset. Furthermore, these methods do not handle the complication that
the disease age at onset may be subject to measurement error, as commonly en-
countered in the studies of neurodegenerative diseases (Garcia, Marder and Wang 
(2017)).
In this paper, we model longitudinal measurements of multiple biomarkers and 
error-corrected clinical diagnosis age simultaneously. Our goal is to identify which 
biomarkers and what features of biomarker trajectories are useful for early diag-
nosis and characterization of disease progression. Specifically, to capture nonlin-
ear sigmoid shape of the biomarker degeneration as observed in empirical studies 
(Jack et al. (2010), Jedynak et al. (2012)), we assume that subject-specific trajec-
tories of biomarkers are related to latent states of underlying neuron masses. This 
assumption is motivated by neural mass models (Hopfield (1982)), where neurons 
are considered as binary units in an active or inactive state and the population-level 
model of their activities is considered as aggregate activities of massive number of 
neurons. Furthermore, we allow biomarker-specific lead time between the disease 
onset and the peak degeneration ages of the biomarkers (inflection points where 
the maximal change of biomarker occurs) to vary across biomarkers and allow in-
flection points to depend on subject-specific covariates. We show that biomarker 
inflection points are useful for early diagnosis of neurological diseases. In addi-
tion, since biomarker at the peak degeneration age is most sensitive to change and 
easiest to be detected, inflection points indicate the optimal timing of intervention 
when designing clinical trials if the inflection point occurs prior to disease onset 
and closely monitoring is available. Furthermore, we show that the biomarker-
specific lead time is an important feature to characterize disease progression.
To accommodate measurement error of the clinical diagnosis age, we assume an 
additive measurement error model. To bypass a difficult nonlinear optimization in 
our modeling, an EM algorithm with explicit solutions in the M-step is developed 
for maximum likelihood estimation. We conduct simulation studies to examine 
the performance of the proposed estimators and show that Bateman et al. (2012) 
approach to impute unobserved disease onset ages may lead to large bias in the 
biomarker trajectories and an increased variability in the estimation of parameters. 
Finally, we apply our methods to two studies of neurodegenerative diseases (HD 
and AD), where we identify biomarkers with peak degeneration ages occurring 
significantly earlier than clinical disease onset so that they can potentially serve as 
early diagnostic markers.
2. Motivating examples.
2.1. HD and predictors of Huntington’s disease (PREDICT-HD) study. HD  
is an autosomal dominant neurodegenerative disease caused by an expansion of 
the cytosine-adenine-guanine (CAG) in the first exon of huntingtin (HTT) gene  
(MacDonald et al. (1993)). Whereas unaffected persons have a range of 6–35 CAG 
repeats, persons affected with HD have 36–121 CAG repeats length (Kremer et al.
(1994), Rubinsztein et al. (1996)). HD has a broad impact on a person’s functional
abilities and usually results in movement, cognitive and psychiatric impairments.
Even though CAG repeats length and baseline age are recognized as important
predictors of HD diagnosis, much effort is needed to refine the prediction of the
age at motor onset.
The PREDICT-HD study is a prospective observational study of premanifest
HD individuals who carry an expansion of CAG repeats (thus at risk of HD)
but without a clinical diagnosis at the baseline (Paulsen et al. (2014b)). These
presymptomatic, gene-positive individuals were recruited starting in 2002 and fol-
lowed for up to 12 years. During the follow-up period, various longitudinal mea-
sures in five domains (motor, cognitive, psychiatric, functional, and imaging) were
collected. The onset of HD was determined by the motor symptoms evaluated on
the Unified Huntington’s Disease Rating Scale (UHDRS) by a trained neurologist.
A subject rated as 4 on the diagnostic confidence level (DCL) is diagnosed with
HD. However, the presence of variation in patients’ motor symptoms and raters’
diagnosis has made clinical diagnosis difficult (Garcia, Marder and Wang (2017)):
a patient could receive a DCL of 4 (diagnosed with HD) at one visit, but fail to
reach a DCL of 4 at the next visit if the patient expresses less motor symptoms
(free of HD diagnosis). In the PREDICT-HD study, 63 (4.6%) patients had such
reversion of diagnosis. Therefore, the observed HD age at onset determined by a
neurologist is an approximation of a patient’s true disease age at onset. Our pro-
posed method will account for the random measurement errors in diagnosis age
using a linear model with a known variance estimated from the incidences of dis-
ease status change in the PREDICT-HD study.
2.2. AD and Alzheimer’s disease neuroimaging initiative (ADNI) study. AD
is an irreversible neurodegenerative disease that results in a loss of cognitive func-
tion due to the deterioration of brain neuronal synapses. The progression of AD has
been divided into three phases. The first phase is a pre-symptomatic phase where
individuals are cognitively normal but some have AD pathological changes. The
second prodromal phase, often referred to as mild cognitive impairment (MCI), is
characterized by the onset of the earliest cognitive symptoms that do not meet the
criteria for dementia. The final phase in the evolution of AD is dementia, defined
as impairments in multiple domains that are severe enough to produce loss of func-
tion. To determine the sequence of pathological changes of AD, a sigmoid model
was proposed and widely used for major AD biomarkers (Jack et al. (2010)). Al-
though some agreement between the temporal ordering of major biological cascade
has been reached, there is no method to precisely estimate the lead time between
when the peak biomarker degeneration occurs (inflection point) and dementia di-
agnosis, accounting for censoring and error in dementia diagnosis.
Data used in the preparation of this article were obtained from the ADNI
database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private
partnership, led by Principal Investigator Michael W. Weiner, MD. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of 
mild cognitive impairment (MCI) and early AD. In three phases of the study 
(ADNI1, ADNI GO, and ADNI2), early mild cognitive impairment (EMCI), MCI, 
mild AD, and normal control subjects were recruited. Biomarkers, such as brain 
scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid were col-
lected to track the progression of the disease. MCI was determined if the subject 
has Mini-Mental State Exam (MMSE) score between 24–30, a memory complaint, 
objective memory loss measured by education adjusted scores on Wechsler Mem-
ory Scale Logical Memory II, a Clinical Dementia Rating (CDR) of 0.5, absence of 
significant levels of impairment in other cognitive domains, essentially preserved 
activities of daily living, and an absence of dementia. Dementia was determined 
if the subject has MMSE score between 20–26, CDR of 0.5 or 1.0, and meets 
NINCDS/ADRDA (National Institute of Neurological and Communicative Disor-
ders and Stroke and the Alzheimer’s Disease and Related Disorders Association) 
criteria for probably AD.
Similar to HD, random variations of the clinical diagnosis of MCI and demen-
tia were observed. Sources of the variations include normal aging independent of 
AD, “cognitive reserve” due to education-linked factors, and disease heterogeneity 
(Nelson et al. (2012)). In the ADNI study, 75 (4.3%) patients had received a diag-
nosis of MCI or AD at one visit, but was then diagnosed as normal at the next visit. 
Similarly to the PREDICT-HD study, the known variance in the measurement er-
ror model can be estimated using the observations of disease status change in the 
ADNI study.
3. Method.
3.1. Latent suppression state model for progression markers. We consider K 
neurological disease markers measured over time from n independent subjects. 
For subject i, we let  Yik(t) be the measurement from the kth marker at age t 
for k = 1, . . . ,K  and let Wi denote the underlying unobserved true disease age 
at onset. Additionally, we let Zi denote a vector of baseline covariates for sub-
ject i. Our first model is to assume that in the population the disease onset follows
Wi ∼ N(θTXi, σ 2W ), where  Xi = (1, ZiT )T . Given  Wi and Zi , our models for K 
disease markers are motivated by the neural mass models in Hopfield (1982). Neu-
ral mass model was used to describe the aggregate activities of massive number of 
neurons. This approach motivates the population-level model by considering neu-
rons as binary units in an active or inactive state. Assuming neuronal responses 
rest on a threshold of activity, any unimodal distribution of thresholds results in 
a sigmoid activation function at the population, following trajectories similar to 
those observed empirically for many neurological disease progression markers 
(Jack et al. (2010)).
Specifically, we assume that marker Yik(t) reflects the activity levels of neuron
mass at age t and such levels further depend on the latent suppression status as sug-
gested in the neural mass model. The suppression status of the neuron mass may be
permanent or instantaneous, where the former most likely associates with suscep-
tibility to neurodegeneration and the latter most likely associates with progression
of neurodegeneration. Let Qik indicate the presence of the permanent suppres-
sion of the neuron mass (for instance, due to genetic mutation, neuronal injury, or
nerve damage) and let Hik(t) indicate the instantaneous suppression at age t (for
instance, due to neurofibrillary tangles). When subject i has no permanent sup-
pression (i.e., Qik = 0), or does not experience any instantaneous suppression at
age t (i.e., Hik(t) = 0), we assume a linear declination trend due to normal aging
process as suggested in Fjell et al. (2009). That is, when Qik = 0 or Hik(t) = 0,
we assume a linear mixed effects model for Yik(t):
Yik(t) = α0k + βkt + νik + εik(t),
where νik is the subject- and marker-specific random intercept following a mean-
zero normal distribution with unknown variance σ 2kν , and εik(t) is a white noise
process with variance σ 2kε . When suppression is present at age t , either due to the
permanent suppression (i.e., Qik = 1) or the instantaneous suppression at age t
(i.e., Qik = 0, Hik(t) = 1), a further reduction in Yik(t) occurs due to disease
degenerative process (Fjell et al. (2009)). Thus, we assume that the marker level
at age t is further reduced by a subject-specific value, αT1kXi . In other words,
depending on the latent suppression states, our progression model assumes
Yik(t) = α0k + αT1kXi
{
Qik + (1 − Qik)Hik(t)}+ βkt + νik + εik(t)
for k = 1, . . . ,K .
To model the distribution of Qik and Hik(t), we first assume that Qik is inde-
pendent of Wi and satisfies the following logistic regression model:
logit Pr(Qik = 1|Xi ) = ηTk Xi .
Since the instantaneous suppression is most relevant to the disease progression, we
let Hik(t) depend on disease age at onset Wi through
Pr
(
Hik(t) = 1|Qik = 0,Wi)= 1
1 + exp{−bk(t − μk − Wi)} ,
where bk is an unknown parameter. Since the above sigmoidal model has an inflec-
tion point at t∗i = μk + Wi , the risk of experiencing an instantaneous suppression
of the neuron mass increases over age, accelerates near age t∗i until reaching its
peak at t∗i , and then the risk remains to increase but at a decelerated speed after-
wards. Moreover, if μk < 0, the peak suppression age has a lead time of |μk| prior
to the disease onset. This suggests that the marker degeneration peaks before the
disease onset, so it can potentially be used for early diagnosis. On the contrary,
if μk > 0, the inflection point age is after Wi , so the marker degeneration peaks
after the disease onset, suggesting that this marker may be more likely to manifest
a post-disease onset effect. Clearly, |μk| gives a magnitude of the lead time or lag
time. For the purpose of early diagnosis, we aim to identify the progression marker
with μk < 0 and estimate the magnitude of |μk| to inform clinical trial design and
recruitment.
REMARK 3.1. From the proposed latent state models, the conditional mean











1 + exp{−bk(t − Wi − μk)}
]
+ βkt.
Thus, the smoothed trend of the marker measurement Yik(t) is a sigmoid function
with a linear drift over age. The peak degeneration age, t∗i = μk + Wi , coincides
with the inflection point of the smoothed marker trajectory, which is the age of the
maximal deterioration of the trajectory. Therefore, by monitoring the marker val-
ues with μk < 0 and identifying the peak age of deterioration, one can make early
diagnosis with |μk| time units ahead of the disease onset in individuals. Note that
existing literature suggests that many neurological biomarkers manifest a nonlin-
ear sigmoid shape (Jack et al. (2010), Jedynak et al. (2012), Samtani et al. (2012),
Paulsen et al. (2014a)), which is consistent with our model of Yik(t) given Wi .
3.2. Likelihood-based estimation and inference. In our applications of HD
and AD studies, the biomarkers are collected longitudinally at discrete time
points and some biomarkers may not be measured at the same time as the oth-
ers. We assume that for i = 1, . . . , n, biomarker k (k = 1, . . . ,K) is measured
at {ti1k, . . . , ti,nik,k}, where nik is the number of measurements. We use Yijk for
Yik(tijk). Another complication commonly encountered in the studies of neuro-
logical diseases is that the disease diagnosis relies on clinical assessments which
are known to be imprecise. Therefore, the clinically diagnosed age at onset, de-
noted by Ti , is the true age at onset measured with error. Particularly, we assume
that the measurement error δi is additive and normally distributed with known con-
stant variance σ 2δ that can be determined a priori using observed data of clinical
diagnosis or from existing literature, that is,
Ti = Wi + δi, δi ∼ N(0, σ 2δ ).
Additionally, we assume that Ti is subject to right censoring due to the end of the
study or patient’s loss of follow-up. Let Ci denote the censoring age, such that we
observe Ỹi ≡ min(Ti,Ci) and i ≡ I (Ti ≤ Ci). The observed data from subject i
consist of
Oi = {tijk, Yijk,Zi , Ỹi ,i : k = 1, . . . ,K; j = 1, . . . , nik}.
Let φ(·;σ 2) and 
(·;σ 2) denote the density function and cumulative distribu-
tion function of N(0, σ 2), respectively. Write αk = (α0k,α1k). Define gijk(Wi;
μk, bk) = exp{−bk(tijk − Wi − μk)},












νik,Wi;μk, bk,αk, σ 2kε
)
= gijk(Wi;μk, bk)Bijk(νik;α0k, σ
2
kε) + Aijk(νik;αk, σ 2kε)
1 + gijk(Wi;μk, bk) .
Assuming that Ci is independent of Ti , Wi , and Yijk given Zi , the observed-data
likelihood function concerning the parameters (αk, βk, σ 2kν, σ
2
kε,ηk,μk, bk) (k =
















































)= φ(Wi − θTZi;σ 2W )φ(Ỹi − Wi;σ 2δ )i
(Wi − Ỹi;σ 2δ )1−i .
We propose to maximize the likelihood function for parameter estimation. To
compute the maximum likelihood estimates, we apply an EM algorithm treating
Qik , νik , Hi1k, . . . ,Hi,nik,k , and Wi (i = 1, . . . , n; k = 1, . . . ,K) as missing data,
where Hijk = Hik(tijk). The details of the EM algorithm are described in the Ap-
pendix A.
Asymptotically, all parameter estimators are consistent and efficient following
the standard maximum likelihood theory, provided that the model parameters are
identifiable and the Fisher information matrix is nonsingular. In particular, we
prove the identifiability in Section S.1 of the Supplementary Material (Gao, Wang
and Zeng (2019)). Due to the lack of an analytical form, we estimate the covari-
ance matrix of the estimators through the nonparametric bootstrap. Specifically,
for each bootstrap, we sample n subjects with replacement. The covariance matrix
is then estimated by the sample covariance matrix of the bootstrap estimators.
3.3. Early diagnosis of disease onset. Given the fitted model, the identified 
biomarkers with peak degeneration ages occurring before the disease onset can be 
used for disease monitoring and contribute to early diagnosis. In addition, we are 
able to predict the precise disease age at onset given observations of biomarkers. 
For a future subject who has not been diagnosed at age t with biomarker mea-
surements Y k ≡ (Y1k, . . . , Ynk ,k) (k = 1, . . . ,K) measured at t1k, . . . , tnk ,k prior 
to age t , the disease age at onset can be predicted given the biomarkers and the 
diagnosis information. That is, we predict the disease age at onset W by the poste-
rior mean of W given the biomarker measurements and the diagnosis information, 
E(W |Y 1, . . . ,  Y K , T  ≥ t), which is given by∫
wψ(w)dw,
where ψ(w) is the posterior density function of the disease age at onset W that is
given by
φ(w − θTZ;σ 2W)
(w − t;σ 2δ )
∏K
k=1 qk(w;ηk,μk, bk,αk, σ 2kε, σ 2kν)∫
φ(W − θTZ;σ 2W)
(W − t;σ 2δ )
∏K
k=1 qk(W ;ηk,μk, bk,αk, σ 2kε, σ 2kν) dW
,
and the integral can be evaluated by numeric integration with Gauss–Hermite
quadratures.
4. Simulations. We conducted simulation studies to examine the perfor-
mance of the proposed methods. A detailed description of the simulation pro-
tocol is given in Section S.2 of the Supplementary Material. We considered
K = 2 biomarkers and generated two independent covariates Zi1 ∼ N(0,1) and
Zi2 ∼ Bernoulli(0.5) for i = 1, . . . , n. We generated the censoring age Ci from
Uniform[0,10]. For each biomarker k and each subject i, we randomly chose
nik from {3, . . . ,10} with equal probabilities and randomly generated tijk (j =
1, . . . , nik) independently from Uniform[0,Ci].
We generated the data from the proposed models, with the values of the param-
eters given in the second column of Table 1 and σ 2δ = 0.2. The censoring rate is
about 30%. We set n = 200 or 400 and used 1000 replicates. The algorithm was
regarded as converged if the maximum of the norms of the parameter differences
in adjacent iterations is smaller than 0.001. For each simulated dataset, 100 boot-
strapped datasets were used for variance estimation.
Tables 1 summarizes the simulation results, where the algorithm converged for
all simulated datasets. Bias and SE are the median bias and standard error, re-
spectively, of the parameter estimator, SEE is the median of the standard error
estimator, and CP is the coverage probability of the 95% confidence interval. The
biases for all parameter estimators are small and decrease as n increases. The vari-
ance estimators for α0k , α1k , βk , μk , bk , θ , and σ 2W are accurate, especially for
large n. The variance estimator for ηk slightly overestimates the true variabilities,
TABLE 1
Summary statistics for the proposed estimators in simulations
n = 200 n = 400
True
Parameter value Bias SE SEE CP Bias SE SEE CP
α01 0.4 −0.016 0.115 0.122 0.958 0.004 0.086 0.083 0.944
α02 0.6 0.005 0.106 0.107 0.945 0.000 0.076 0.072 0.928
α11 1.0 0.020 0.123 0.130 0.957 −0.003 0.089 0.090 0.944
0.8 −0.005 0.059 0.062 0.956 −0.002 0.043 0.043 0.945
0.7 −0.006 0.114 0.118 0.954 0.003 0.083 0.082 0.939
α12 1.0 0.004 0.125 0.127 0.947 −0.004 0.089 0.088 0.933
1.2 −0.001 0.063 0.064 0.943 −0.001 0.046 0.044 0.933
0.8 0.003 0.121 0.125 0.958 0.000 0.084 0.087 0.947
β1 0.8 0.001 0.017 0.017 0.950 0.000 0.012 0.012 0.953
β2 −0.4 0.001 0.014 0.014 0.951 0.000 0.010 0.010 0.958
σ 21ε 0.5 −0.005 0.031 0.031 0.950 0.000 0.021 0.022 0.956
σ 22ε 0.5 −0.003 0.025 0.026 0.957 −0.001 0.018 0.018 0.949
σ 21ν 0.5 −0.009 0.066 0.067 0.956 −0.005 0.048 0.047 0.945
σ 22ν 0.5 −0.014 0.070 0.067 0.933 −0.005 0.049 0.048 0.944
η1 −0.5 0.006 0.628 0.751 0.989 −0.014 0.423 0.442 0.974
0.5 0.004 0.383 0.459 0.989 −0.003 0.259 0.266 0.967
0.0 −0.012 0.550 0.642 0.990 0.018 0.393 0.395 0.958
η2 0.0 −0.011 0.462 0.483 0.979 −0.001 0.300 0.304 0.970
−0.5 −0.021 0.298 0.320 0.985 −0.001 0.198 0.196 0.966
0.5 0.000 0.489 0.509 0.971 0.009 0.330 0.329 0.956
μ1 −1.0 0.003 0.416 0.431 0.972 −0.002 0.290 0.292 0.951
μ2 1.6 −0.030 0.466 0.455 0.948 0.001 0.292 0.316 0.969
b1 −0.5 −0.006 0.115 0.116 0.962 −0.003 0.074 0.075 0.954
b2 0.5 0.006 0.088 0.090 0.964 0.001 0.056 0.061 0.962
θ 3.0 0.001 0.071 0.072 0.953 0.002 0.052 0.051 0.942
−0.2 0.000 0.052 0.052 0.946 −0.001 0.037 0.036 0.938
0.2 0.001 0.099 0.103 0.953 −0.002 0.074 0.073 0.946
σ 2W 0.2 −0.010 0.047 0.044 0.943 −0.008 0.033 0.031 0.942
but it gets more accurate as sample size increases. The confidence intervals have
satisfactory coverage probabilities when the sample size is large (n = 400).
To evaluate the performance of the proposed prediction procedure, for each sim-
ulation replicate, we generated an independent data set of sample size 2000. The
data were generated in the same manner, except that we included only censored
subjects. We predicted the disease age at onset for the censored subjects in the new
dataset using the parameter estimators from the original replicate and compared
the predicted ages at disease onset with the true disease onset ages. In addition, we
calculated the average logarithmic score (Good (1952), Bernardo (1979), Gneiting,
Balabdaoui and Raftery (2007)), which is the average of the negative logarithm of
TABLE 2
Summary statistics on prediction in simulations
n = 200 n = 400
Adjusted Adjusted Adjusted Adjusted
Prediction Bias SD LS Bias SD LS
Both biomarkers 0.001 0.079 0.036 −0.002 0.052 0.020
Biomarker 1 0.001 0.084 0.038 −0.002 0.060 0.022
Biomarker 2 0.001 0.085 0.037 −0.002 0.061 0.022
the predictive density function evaluated at the true disease onset age, such that
a smaller value indicates a better fit. We compared the results with the proposed
models with both biomarkers and one biomarker only.
Table 2 shows the mean prediction error, adjusted standard deviation (adjusted
SD), and the mean adjusted logarithmic score (adjusted LS), where the adjusted
SD is calculated as the squared root of mean squared prediction error minus the in-
trinsic prediction error variability that is estimated as the mean squared prediction
error using the conditional mean of the disease age at onset given the diagnosis,
and the adjusted LS is calculated as the logarithmic score minus that from the
two-biomarker model with the true parameter values. The biases from all models
are small. The adjusted SD and adjusted LS decrease as n increases. The adjusted
LS based on both biomarkers is lower than those based on the models with one
biomarker. Compared to those from the models with one biomarker only, the pre-
diction based on both biomarkers has smaller variability: for n = 400, the improve-
ment in prediction efficiency of using both biomarkers is about 15%.
5. Applications.
5.1. HD and PREDICT-HD study. We applied the proposed methods to the
aforementioned PREDICT-HD study. We included three motor markers (Ocular,
Brady, and Chorea) measuring impairment in movement and three cognitive mark-
ers (SDMT, Stroop-WO, and Smell-ID) measuring impairment in cognition. Ocu-
lar, Brady, and Chorea are the ocular, bradykinesia, and chorea subscales from the
UHDRS, reflecting ratings of eye movement and tracking, abnormal slowness or
rigidity of movement, and abnormal involuntary movement disorder, respectively
(Huntington Study Group (1996)). SDMT is the symbol digit modalities test that
measures working memory, complex scanning, and processing speed. Stroop-WO
is the stoop word test that measures basic attention and processing speed. Smell-ID
is the University of Pennsylvania smell identification test that measures the olfac-
tory recognition. The covariates Zi for HD age at onset include baseline age, years
of education, gender, and length of CAG repeats.
We included 1073 gene-positive subjects with more than 35 CAG repeats at
huntingtin gene in the analysis. During the follow-up, 225 (21%) subjects devel-
oped HD and the age at disease onset is defined as the age of the first observation
with DCL = 4. For each marker, on average more than three measurements are
available for each subject. We estimated the magnitude of measurement error σ 2δ
of HD diagnosis from the PREDICT-HD study. In particular, we fitted the adjacent
observations with status change (from DCL < 4 to DCL = 4, or reverse) by a gen-
eralized linear model to obtain σ 2δ = 0.324. The details of the estimation procedure
are given in Section S.3 of the Supplementary Material.
Table 3 shows the estimation results for various parameters associated with the
peak degeneration ages and HD age at onset, where 1000 bootstrap samples were
used for variance estimation. Male subjects have later HD age at onset than fe-
males. Longer years of education and shorter CAG repeats length are associated
with later HD age at onset. The inflection of the three motor measures occur close
to HD age at onset, with the 95% confidence intervals of the lead times containing
zero. These results are expected since the motor scores measure a patient’s motor
symptoms and HD diagnosis is also mainly based on motor function. In addition,
this finding is also consistent with the existing literature suggesting that subtle mo-
tor abnormalities accelerate just prior to diagnosis (Long et al. (2014)). The symbol
digit modalities and stroop word cognitive tests, which have respective lead times
approximately 2 and 1.5 years before HD onset and significantly earlier than HD
onset, can be candidate markers for early detection of HD diagnosis.
Next, we examined the differences of biomarker values and peak degenera-
tion ages among subgroups of subjects. Figure 1 shows the average estimated
biomarker values among the subgroups of subjects with different CAG repeats
length. Subjects with a longer CAG expansion are associated with an earlier HD
TABLE 3
Estimation results for selected parameters in the PREDICT-HD study
Parameter Est SEE p-value
μk Ocular 0.208 0.390 0.593
Brady −0.158 0.278 0.570
Chorea −0.008 0.275 0.977
SDMT −2.194 0.676 0.001
Stroop-WO −1.535 0.697 0.028
Smell-ID −0.963 0.807 0.232
θ Intercept 64.23 5.533 <0.0001
Baseline age 0.738 0.025 <0.0001
Years of education 0.182 0.071 0.010
Sex (Male) 0.881 0.416 0.034
CAG repeats length −1.090 0.107 <0.0001
σ 2W 18.89 1.754 <0.0001
FIG. 1. Average estimated values of biomarkers over age among subgroups of subjects with dif-
ferent lengths of CAG expansion. The black solid, red dashed, and blue dotted curves pertain to the
subgroups of subjects with CAG expansion < 41, 41 ≤ CAG expansion < 43, and CAG expansion ≥
43, respectively. The circles and bars indicate the average inflection points and their 95% confidence
intervals. The dashed vertical lines indicate the average HD age at onset. SDMT and Stroop-WO are
identified as prognostic biomarkers using the proposed approach.
age at onset and an earlier peak degeneration age for all considered biomarkers. In
particular, subjects with CAG expansion < 41, 41 ≤ CAG expansion < 43, and
CAG expansion ≥ 43 have peak degeneration ages of symbol digit modalities test
at approximate 57, 50, and 41 years old, respectively, with corresponding scores
46, 44, and 42. Those subjects have peak degeneration ages of stroop word cog-
nitive test at approximate 58, 51, and 42 years old, with corresponding scores 90,
86, and 84.
Finally, we examined the performance of the proposed methods on the predic-
tion of HD age at onset given the biomarker measurements. Figure 2 presents the
difference of the predicted HD age at onset and the observation age for each in-
dividual. For the noncensored subjects, the difference between the predicted and
observed HD age at onset is within the measurement variability of Ti (within the
distance of
√
σ 2δ + σ 2W ). For the censored subjects, most of the predicted HD age at
onset is beyond the lower limit of the censoring age considering variability of the
disease age at onset (i.e., beyond censoring age minus
√
σ 2δ + σ 2W ). The proposed
methods thus provide adequate fit to the PREDICT-HD data.
FIG. 2. Difference of the predicted HD age at onset and the observation age versus the observa-
tion age in the PREDICT-HD study. The red circles and black crosses pertain, respectively, to the
uncensored and censored subjects. The blue dashed lines indicate variability ±
√
σ 2δ + σ 2W .
5.2. AD and ADNI study. We applied the proposed methods to the aforemen-
tioned ADNI study. We analyzed the combined MCI and AD as a composite event,
which serves as an alternative definition of early AD as suggested by Dubois et al.
(2007). We considered four markers: the Montreal Cognitive Assessment (MOCA)
that assesses several cognitive domains; the Clinical Dementia Rating Sum of
Boxes (CDRSB) that measures the staging severity of dementia; the Functional
Activities Questionnaire (FAQ) that serves as a screening tool for evaluating activ-
ities of daily living; and the Aβ42 protein level (ABETA) measured from the cere-
brospinal fluid. We associated the markers and early AD age at onset to baseline
age, gender, education, number of APOE ε4 alleles, baseline Alzheimer’s Disease
Assessment Scale 11 terms total scores (TOTAL11), and baseline FAQ.
We included 414 subjects who were cognitively normal at the baseline, out of
whom 87 (21.0%) subjects developed early AD during the follow-up. For each
marker, more than two measurements are available for each subject. We estimated
the magnitude of the measurement error using the generalized linear model as
described in Section S. 3 in the Supplementary Material to obtain σ 2δ = 1.47.
Table 4 shows the estimation results of various parameters associated with the
peak degeneration ages and age at early AD onset. Carriers of APOE ε4 alleles
have a younger early AD age at onset than noncarriers, and larger values of base-
line TOTAL11 and baseline FAQ are associated with younger age at onset. The
peak degeneration ages of MOCA, FAQ, and CDRSB occur later than early AD
onset. For ABETA, the peak degeneration occurs approximately 12 years before
onset, suggesting that it is a candidate for early detection of early AD. This find-
ing agrees with the hypothesis that Aβ-plaque deposits are early events in the AD
TABLE 4
Estimation results for selected parameters in the ADNI study
Parameter Est SEE p-value
μk MOCA 1.622 0.470 0.0006
FAQ 1.558 0.287 <0.0001
CDRSB 1.488 0.255 <0.0001
ABETA −12.09 2.973 <0.0001
θ Intercept 13.14 4.795 0.006
Baseline age 0.956 0.061 <0.0001
Gender −0.310 0.570 0.587
Education 0.136 0.118 0.248
APOE ε4 allele −1.339 0.511 0.009
Baseline Total11 −0.357 0.087 <0.0001
Baseline FAQ −1.233 0.326 0.0002
σ 2W 13.58 2.028 <0.0001
cascade occurring before the appearance of clinical symptoms (Jack et al. (2010),
Bateman et al. (2012)). The estimated lag times also have implications on clinical
trials design. The peak acceleration of MOCA, FAQ, and CDRSB occurs within
about 1.5 years after diagnosis. A clinical trial designed to test changes in these
measures in response to a therapy may recruit newly diagnosed MCI or AD pa-
tients within about 1.5 years to improve power.
Figure 3 shows the average estimated biomarker values among carriers and non-
carriers of APOE ε4 alleles. Carriers are associated with a younger age at onset
and an earlier peak degeneration age for all considered biomarkers. In particular,
carriers and noncarriers have a peak ABETA acceleration at approximate 74 and 76
years of age, respectively. Early AD onset occurs approximately at 82 and 84 years
for the two groups. The corresponding Aβ42 cutoff values are 143 and 183 pg/mL,
which are slightly lower than the recommended threshold for using Aβ42 to define
AD in Shaw et al. (2009) (Aβ42 < 192 pg/mL defined as AD, estimated as the
value that maximizes the area under the receiver operating characteristic curve for
the detection of AD). However, since the diagnostic test based on this threshold
has a relatively high sensitivity (96.4%) and low specificity (76.9%), the reported
cutoff in Shaw et al. (2009) may be anti-conservative.
Lastly, to see the potential bias of using parent’s disease age at onset to impute
offspring’s AD age at onset as the analyses performed in Bateman et al. (2012),
we simulated parent’s age at onset and fit the proposed model. In particular, we
assumed that the parent’s age at onset has the same mean as the child’s age at on-
set estimated from the proposed approach with a correlation of 0.3 or 0.65. For
censored subjects, we imputed their age at onset by their parents’ early AD age
at onset. The simulated parent’s onset age is on average 5.5 and 4.3 years dif-
ferent from the child’s onset age. The red solid and dashed curves in Figure 4
FIG. 3. Average estimated values of biological and clinical markers over age among carriers and
noncarriers of APOE ε4 alleles. The black solid and red dashed curves pertain to the subgroups of
APOE carriers and noncarriers, respectively. The circles and bars indicate the average inflection
points and their 95% confidence intervals. The dashed vertical lines indicate the average early AD
onset ages. Aβ42 is identified as a prognostic biomarker and MOCA, FAQ, and CDRSB are confirmed
as diagnostic markers.
show the average estimated values of biomarkers with censored onset ages re-
placed by imputation as in Bateman et al. (2012), where the black curves show
our proposed approach that handles censoring appropriately. The horizontal axis
is anchored at the estimated age at onset of early AD (years to onset of early AD).
For both scenarios of correlation, imputing censored ages at onset leads to a large
bias of the trajectories of biomarkers, and the estimated biomarker lead times can
be shifted.
6. Discussion. In this paper, we proposed a latent suppression state model to
identify useful biomarkers for early disease diagnosis and estimate lead time to dis-
ease onset or lag time post onset. The proposed model is motivated from biological
models of neural masses, and facilitates inference for modeling nonlinear sigmoid
shapes of biomarker trajectories observed empirically. Furthermore, we proposed
a computationally efficient EM algorithm with explicit solutions in the M-step and
FIG. 4. Average estimated values of biological and clinical markers over centralized age (years
to age at onset of early AD). The black solid curves pertain to the proposed approach with the
observed data. The circles and bars indicate the population average peak degeneration ages and their
95% confidence intervals. The red dashed and blue dotted curves pertain, respectively, to imputing
censored age at early AD by parent’s AD age at onset with a correlation of 0.3 or 0.65 between
child’s and parent’s onset ages.
the evaluation of conditional expectation for the latent variables conducted using
Gaussian quadratures. The numerical integration is at most two-dimensional, even
if a large number of biomarkers are included.
For the asymptotic theory to hold, we require at least two measurements per
biomarker for each subject. Empirically, we found that two measurements per
biomarker for each subject provided stable estimation results for n = 400 (99.5%
of the simulated datasets converged in simulated settings). This requirement on
the number of measurements usually holds for neurological disease studies with
relatively closely monitoring, as for the PREDICT-HD and ADNI studies.
A number of parametric assumptions are suggested to model the disease onset
age and biomarker measurements. For example, we assume a functional relation-
ship between the biomarker and suppression as well as the age at disease onset and
measurement age. This parametric assumption is in fact very simple and standard
and it yields a sigmoid shape of the observed biomarker with a peak degeneration
age that is consistent with empirical observations and existing literature. In addi-
tion, we assume that measurement error for the disease onset age is normal dis-
tributed with known variance. In practice, some of these parametric assumptions
may be violated and further investigation may be needed to study the performance
of the proposed methods under mis-specified models.
In the PREDICT-HD study, we visualize the fit of the proposed model through
comparing the predicted HD age at onset with the observation age graphically.
We also examine the goodness of fit for the model of the biomarkers by plotting
the residuals of the biomarker measurements against the ages at measurements
(Rizopoulos (2012), Chapter 6) in Figures S.1 and S.2 in the Supplementary Ma-
terial. The proposed model is regarded as adequate since the predicted HD age at
onset is consistent with the observation age, allowing for the existence of mea-
surement errors, and the residuals are approximately randomly dispersed. A better
model checking procedure may be developed to assess the goodness of fit of the
proposed model.
In the ADNI study, we examined the performance of the imputation analyses
in Bateman et al. (2012). Since the disease onset ages were observed in non-
censored subjects, imputation was only applied to approximate disease onset for
right-censored subjects. Even if the mean of the early AD age at onset was cor-
rectly specified, the trajectories of biomarkers were estimated with bias, and the
inflection points were shifted (especially for Aβ42). Our proposed methods make
use of the observed diagnosis ages in noncensored subjects, appropriately handle
censoring for those who were not diagnosed, and yield biomarker trajectories and
peak degeneration ages with better accuracy and precision than Bateman et al.
(2012).
The proposed approach, which assumes a normal distribution for the disease age
at onset, can be extended to accommodate other parametric distributions, semi-
parametric distributions, or nonparametric distributions. For example, a propor-
tional hazards model may be assumed for the age of disease onset. In addition, we
may extend the proposed approach to accommodate interval-censored disease age
at onset.
We assumed that the lead times or lag times between the peak degeneration of
the biomarkers and the disease onset are the same for all subjects. This assumption
can be easily relaxed to allow for subject-specific lead or lag times. For exam-
ple, the biomarker model of AD proposed by Jack et al. (2010) hypothesized that
the lag period between Aβ-plaque formation and neurodegenerative cascade may
vary among subjects, indicating differences in Aβ processing, brain resilience, or
cognitive reserve. We may introduce subject-specific fixed effects and random ef-
fects to the sigmoid function to accommodate this general case, but with increased
computational complexity.
APPENDIX A: DETAILS OF THE EM ALGORITHM
Denote Rijk = Qik +(1−Qik)Hijk . The complete-data log-likelihood concern-
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Since the complete-data log-likelihood can be factorized into pieces concerning
disjoint subsets of parameters, we obtain the estimates for subsets of the parame-
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where Ê(·) is the conditional expectation with respect to the observed data. We
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In the E-step, we evaluate the conditional expectations of Ê(Rijk), Ê(νik),
Ê(ν2ik), Ê(νikRijk), Ê(Qik), Ê(Wi), Ê(W
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]
given the observed data Oi for m1 = 0,1,2 and m2 = 1,2. Specifically, the condi-
tional expectation of Qik given νik and Wi is given by
exp(ηTk Xi )
∏nik
j=1 Aijk(νik;αk, σ 2kε)
exp(ηTk Xi )
∏nik
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,
and the conditional expectation of Rijk is given by
exp(ηTk Xi )
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kν)hi(Wi;σ 2W,σ 2δ ). We evaluate the conditional expectations through numer-
ical integration over νik and Wi with two-dimensional Gauss–Hermite quadratures.
We iterate between the E-step and M-step until convergence.
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SUPPLEMENTARY MATERIAL
Supplement A: Supplement to “Early diagnosis of neurological disease
using peak degeneration ages of multiple biomarkers” (DOI: 10.1214/18-
AOAS1236SUPPA; .pdf). This supplement provides additional information on the
theorem and proof on model identifiability, protocol for simulation studies, de-
tails on estimating the magnitude of measurement error, and residual plots of the
examples.
Supplement B: R codes (DOI: 10.1214/18-AOAS1236SUPPB; .zip). Codes
for the EM algorithm and simulation illustrating the proposed methods.
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